The clinical landscape of mental health disorders now includes a promising trial exploring the use of technology for treating trichotillomania, also known as hair-pulling disorder. HabitAware Inc., backed by the National Institute of Mental Health and Kent State University, is investigating the efficacy of the Keen2 Predictive Awareness Bracelet—a behavioral intervention designed to empower individuals through wearable technology.
A detailed update from November 4, 2025, highlights this development, emphasizing the potential impact for clinical, regulatory, and quality assurance professionals monitoring advancements in medical devices for behavioral health.
In this article
- What is the new trial about?
- How does the Keen2 Bracelet work?
- What are the regulatory implications?
- FAQ
- Conclusion
- Disclaimer
- Announcement source
What is the new trial about?
This open trial is actively recruiting to evaluate the effectiveness of the Keen2 Predictive Awareness Bracelet for individuals diagnosed with trichotillomania. Built on behavioral therapy principles, the bracelet is designed to help users recognize and manage compulsive behaviors. With contributions from HabitAware and research partners NIMH and Kent State University, the study aims to pave the way for innovative, non-invasive treatment approaches.
How does the Keen2 Bracelet work?
The Keen2 Predictive Awareness Bracelet functions by detecting repetitive movements and vibrations associated with hair-pulling behaviors. When the device senses these actions, it delivers gentle alerts to the wearer, effectively fostering awareness of the behavior in real-time. This technology supports individuals in breaking habitual cycles by bringing their attention to unconscious behaviors. With this wearable solution, the focus shifts to empowering patients through improved self-management rather than solely relying on professional interventions.
What are the regulatory implications?
As this device moves further along the validation process, regulatory professionals should closely monitor its progress for potential implications in behavioral health treatments. Clearance pathways, data handling requirements, and safety standards will likely gain attention given the device’s sensory technology and behavioral modification approach. Past trials indicated success with similar devices, offering hope for Keen2’s adoption in trichotillomania treatment.
Clinicians and policymakers will be especially interested in the long-term effectiveness and patient compliance rates tied to such wearable interventions.
FAQ
- What is trichotillomania?
Trichotillomania is a mental health disorder characterized by compulsive hair-pulling, often leading to noticeable hair loss and emotional distress. - Who sponsors the trial?
The study is sponsored by HabitAware Inc., the National Institute of Mental Health (NIMH), and Kent State University. - Is the trial recruiting?
Yes, as of November 4, 2025, the trial is actively recruiting participants. - How does the Keen2 Predictive Awareness Bracelet help?
The bracelet detects repetitive movements related to hair-pulling and sends alerts to improve behavioral awareness in users.
Conclusion
The Keen2 Predictive Awareness Bracelet trial underscores an exciting intersection of technology and behavioral health. Professionals in clinical and regulatory fields should stay attentive to its progress, as wearable tech continues to influence patient care strategies worldwide. Ultimately, this research may lead to scalable solutions for trichotillomania and similar conditions.
Disclaimer
This article is for informational purposes only and should not be considered legal advice. For specific regulatory guidance, consult appropriate legal or compliance professionals.
Announcement source
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07224126?term=medical+device